Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P10415 (
Bcl-2
)
33,771
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Apoptosis pathways are known to be involved in the pathogenesis of peripheral T-cell lymphomas (PTCLs). As such, the current study attempted to investigate the overexpression of
Bcl-2
, Bax, or p53 with respect to the progression of PTCL. Paraffin-embedded specimens from 74 patients were analyzed immunohistochemically for
Bcl-2
, Bax, or p53 overexpression including PTCL-unspecified (n=45), extranodal natural killer cell/T-cell lymphoma (n=10),
angioimmunoblastic T-cell lymphoma
(n=7), anaplastic large cell lymphoma (n=7), and cutaneous T-cell lymphoma (n=5). The
Bcl-2
overexpression was exhibited in 33 (45%), Bax, 17 (23%), and p53, 33 patients (45%).
Bcl-2
overexpression was strongly associated with advanced stage (p=0.021) and higher international prognostic indices (IPI) (p=0.038).
Bcl-2
(+)/p53(+) group was found to be associated with advanced stage (p=0.008) and higher IPI (p=0.001), compared with the other groups. The independent expression of
Bcl-2
or p53 was not correlated with survival. Meanwhile, when confined to
Bcl-2
overexpressing groups, p53 overexpression was significantly associated with poor survival (p=0.05), as the 3-year OS rate was 82.5% for
Bcl-2
(+)/p53- cases, yet only 32.9% for
Bcl-2
(+)/p53(+) cases. Multivariate analyses for OS found the
Bcl-2
/p53 co-expression (p=0.004) as independent prognostic factor, together with advanced stage (p<0.001) and higher prognostic index for PTCL (p=0.008).
Bcl-2
overexpression seemed to correlate with the progression of PTCL interacting with a p53-dependent pathway.
...
PMID:Clinical role of Bcl-2, Bax, or p53 overexpression in peripheral T-cell lymphomas. 1667 27